Zepbound

The success of weight loss drugs, particularly Zepbound, has generated a $1.3 billion increase in donations to Christian ministries in the U.S. and Canada. This surge in giving is attributed to the growing popularity of these medications.

UVM Health plans to stop covering weight loss medications for employees starting September 2023, aiming to save $19 million annually. The decision affects GLP-1 drugs like Ozempic and Zepbound, which are costly out-of-pocket for employees, while coverage for diabetes treatment remains. Employees express concern over financial burden and health impacts.

A U.S. judge blocked Colorado from capping the price of Amgen's Enbrel, citing potential harm to the company, while a new Medicare program will offer obesity drugs at $50/month. Novo Nordisk and Eli Lilly's weight-loss treatments will be included in the trial.

Medicare will start covering weight-loss drugs via a temporary pilot program on July 1, allowing millions of enrollees access to medications like Wegovy and Zepbound at significantly reduced costs under a deal with Eli Lilly and Novo Nordisk. The program aims to address obesity as a treatable disease, offering seniors like Mary and Jeff Abrahamson affordable options that improve health outcomes.

A Medicare pilot program expands access to GLP-1 weight-loss medications like Wegovy and Zepbound for some seniors, offering subsidies as high as $50 per month. The program, running through 2027, requires a BMI above 35 or specific weight-related conditions for eligibility, though 6 million Medicare Part D recipients who might otherwise qualify will remain excluded. Concerns persist about potential bone and muscle density loss from rapid weight loss, but medical professionals suggest exercise can mitigate risks.

Medicare is offering select GLP-1 weight loss drugs for $50/month through a temporary trial until 2027, with eligibility based on BMI and specific health conditions. Covered medications include Eli Lilly's Foundayo and Zepbound, and Novo Nordisk's Wegovy, but exclusions apply for those with diabetes or sleep apnea.

Medicare will cover GLP-1 weight-loss treatments through a temporary pilot program starting July 1, allowing eligible participants to pay a $50 monthly co-pay. The program includes Eli Lilly’s Zepbound and Foundayo and Novo Nordisk’s Wegovy, with coverage ending by 2027 due to federal law restrictions. Eligibility requires a BMI of 35 or higher (or 30 with specific health conditions), and prior authorization is needed.

Experts in Charlotte, N.C., are raising concerns about the disposal of GLP-1 injection pens as the use of weight-loss drugs like Ozempic, Wegovy, and Zepbound surges. Studies estimate roughly 12% of U.S. adults are using these medications, prompting questions about post-use waste management.

Medicare will cover weight-loss drugs for the first time starting July 1 through a temporary pilot program called Medicare GLP-1 Bridge. The program aims to reduce costs for medications like Zepbound and Wegovy, which are expensive without insurance, providing financial relief for seniors like Mary and Jeff Abrahamson who previously relied on compounded versions of tirzepatide.

2-year results from the SUPPRESS-EARLY trial indicate that early use of tirzepatide (Mounjaro, Zepbound) in type 2 diabetes management significantly improves outcomes. The findings were presented at the American Diabetes Association annual meeting.

Insurance coverage for GLP-1 weight loss drugs like Zepbound and Wegovy is being dropped by many plans due to high costs, leaving patients to seek alternatives. Patients may retain coverage if the drugs are prescribed for related conditions like sleep apnea or diabetes through prior authorization.

Insurance companies are increasingly dropping coverage for weight loss drugs like Wegovy and Zepbound due to rising costs, pushing patients to purchase through telehealth providers or manufacturers. Hims partners with Wegovy to offer the drug directly, while CVS expands coverage for Eli Lilly's anti-obesity pill and reinstates Zepbound later this year.

A new meta-study compared three GLP-1 medications: tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda, Victoza). The study evaluated their effectiveness in a head-to-head analysis.

A new meta-study compared three GLP-1 medications: tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda, Victoza).

A new meta-study compared three GLP-1 medications: tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda, Victoza) to determine their effectiveness.

GLP-1 weight loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound are popular, prompting competitors like Pfizer and Amgen to develop similar products. The article discusses market competition and strategies by Novo Nordisk and Eli Lilly to maintain dominance in the weight loss drug sector.

People taking GLP-1 weight-loss drugs like Ozempic, Wegovy, Mounjaro, and Zepbound may experience reduced physical activity despite weight loss, according to Fitbit data analysis. Researchers noted declines in daily steps and exercise levels, raising concerns about muscle mass loss and long-term health impacts.

Some employers plan to drop coverage of GLP-1 weight loss drugs in 2027 as usage rises, despite lower prices for medications like Novo Nordisk’s Zepbound and Eli Lilly’s Foundayo. Rapid adoption of GLP-1 drugs in the U.K. has reduced annual grocery spending by $1 billion, with 6.3% of households now including at least one user.

A study presented at the American Society of Clinical Oncology conference suggests GLP-1 weight-loss drugs like Wegovy and Zepbound may reduce breast cancer risk by over 30% in women. The observational study analyzed health records of 111,000 women and found those prescribed GLP-1 medications had significantly lower breast cancer incidence, though researchers caution the findings do not prove causation.

California's Senate passed a bill requiring health insurers to cover GLP-1 weight-loss drugs like Ozempic for public employees, but CalPERS opposes it due to projected $437 million premium increases and $187 million state fund costs. Sen. Laura Richardson advocates for a five-year pilot program to cover chronic weight management treatments, citing potential long-term savings from reduced healthcare costs.

Boehringer Ingelheim's obesity drug survodutide showed 13% weight loss in a Phase 3 trial, lower than Novo Nordisk's Wegovy and Eli Lilly's Zepbound. While the drug reduced liver fat by 63%, it appears less efficacious and tolerable compared to existing treatments.

New experimental weight-loss drugs are being developed to improve upon existing GLP-1 therapies like Zepbound and Wegovy. These therapies aim to offer better alternatives for patients experiencing nausea or daily pill regimens.

A large study found women taking GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound had a 30% lower breast cancer risk. Researchers note the findings are promising but not definitive, with clinical trials planned to test the drugs' preventive potential.

Pfizer's obesity drug berobenatide, acquired from Metsera, showed continued weight loss when transitioning from weekly to monthly dosing in a mid-stage study. Patients lost up to 12.1% of their weight by 28 weeks, but the rate lagged behind Eli Lilly's Zepbound trial results.

Cigna will stop covering GLP-1 weight loss drugs like Wegovy and Zepbound in its employee health plan starting July 1, directing users to cash-pay options. A study suggests long-term use of GLP-1 drugs could reduce knee replacement risk by up to 5% over eight years. Prices for these drugs are declining in 2026 with new oral versions.

Medicare is promoting GLP-1 drugs Wegovy and Zepbound for weight loss starting July 2024 at $50/month for older adults but has not disclosed the total cost to taxpayers. Massachusetts has filed a lawsuit against United, though details are unspecified in the excerpt.

Medicare will cover Wegovy and Zepbound for weight loss starting July 2024 at $50/month for beneficiaries, but has not disclosed the cost to taxpayers. The temporary 'GLP-1 Bridge' program, running until December 2027, bypasses federal law and shifts most costs to taxpayers. The Trump administration initially planned coverage through Medicare Advantage plans, but insurers opposed due to high costs.

CVS will cover Lilly’s GLP-1 medications, Foundayo (a pill) and Zepbound (an injection), potentially expanding access for millions of Americans.

The article discusses upcoming public visibility of drug prices under Trump's most-favored-nation deals, highlighting three new drugs (Baxfendy, Awiqli, and Veppanu). CVS Health is reintroducing Eli Lilly's obesity drug Zepbound to formularies and removing coverage restrictions on Lilly's new weight loss pill Foundayo.

CVS Caremark has resumed coverage of Eli Lilly's weight loss drug Zepbound following patient backlash over its initial decision to stop covering the medication. The reversal highlights patient advocacy influencing healthcare policy.

CVS Health will add Zepbound coverage starting October 1 and begin covering Eli Lilly's newly approved obesity treatment, Foundayo, on June 1. The moves expand drug plan accessibility for weight management medications.

Eli Lilly announced clinical trial results for retatrutide, demonstrating that study participants lost an average of 70 lbs over 80 weeks. The drug shows greater efficacy than competing obesity medications Zepbound and Wegovy, positioning it as a more powerful next-generation treatment option.

Eli Lilly's late-stage obesity drug trial showed weight loss comparable to bariatric surgery but with concerning discontinuation rates of 11% due to adverse events, nearly double competitors' rates. A statistical technique called quantile aggregation used in Alzheimer's drug analyses may be overstating relationships between amyloid levels and cognitive outcomes.

Eli Lilly has developed an experimental weight loss injection that achieved 28% weight loss in trials. The new shot differs from existing medications Zepbound and Foundayo by combining three active components: GIP, GLP-1, and glucagon.

Eli Lilly's obesity drug retatrutide demonstrated weight loss comparable to bariatric surgery in Phase 3 trials, with patients losing up to 28.3% of body weight after 80 weeks. However, the treatment showed concerning side effects with 11% discontinuation rates on the highest dose, significantly higher than competing drugs like Wegovy and Zepbound.

Medicare beneficiaries may be able to get a GLP-1 prescription for weight loss for $50 a month starting in July, a notable shift for Medicare which has long been barred from covering weight loss treatments. The drugs, such as Wegovy and Zepbound, are effective but can be expensive without insurance coverage. This new benefit is part of the Medicare GLP-1 Bridge program, a short-term pilot program.

Twelve million people lost coverage for obesity drugs Zepbound and Wegovy over the last year, according to an analysis by GoodRx. The restrictions have forced patients to adjust their treatment options.